895240-72-9

Basic information

• Product Name: Benzoic acid, 3-(3-methoxypropoxy)-4-methyl-, methyl ester
• CAS NO: 895240-72-9
• Molecular Formula: C13H18O4
• Molecular Weight: 238.284
• Mol File: 895240-72-9.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: Benzoic acid, 3-(3-methoxypropoxy)-4-methyl-, methyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: Benzoic acid, 3-(3-methoxypropoxy)-4-methyl-, methyl ester(895240-72-9)
• EPA Substance Registry System: Benzoic acid, 3-(3-methoxypropoxy)-4-methyl-, methyl ester(895240-72-9)

Safety Data

• Hazardous Substances Data: 895240-72-9(Hazardous Substances Data)

Upstream product

• 586-30-1 3-hydroxy-4-methylbenzoic acid 
• 1589-49-7 methoxypropanol 
• 3556-86-3 methyl 4-methyl-3-hydroxybenzoate 
• 61542-10-7 1-iodo-3-methoxypropane 

Downstream Products

• 857272-47-0 [3-(3-methoxy-propoxy)-4-methyl-phenyl]-methanol 
• 1056676-61-9 4-bromomethyl-2-(3-methoxy-propoxy)-1-methyl-benzene 
• 895240-71-8 3-(3-methoxy-propoxy)-4-methyl-benzoic acid 

Relevant articles and documents

ASPARTYL PROTEASE INHIBITORS

The invention provides compounds of the formula (I) wherein A is selected from the partial structures A1, A2 and A3; Ry and Ry' are both hydrogen, or Ry and Ry' together with the nitrogen atom to which they are attached form a cyclic amine such as morpholine, piperidine, piperazine or pyrrolidine; L is NHNH, CH2NH, O or S; Y is NH, NHNH, NHC(=O), S(=O)2NH, NHS(=O)2, CH2, CH2NH, O, S or S(=0)p; Q is aryl or heterocyclyl; Z is O, S, NRa or S(=0)p; m is O, 1 or 2; n is O, 1, 2 or 3; p is independently 1 or 2; q is 0 or 1; Ra is H or C1-C4alkyl; R1 is hydrogen, C1-C6alkyl, C3-C7cycloalkylC0-C3alkyl, arylC0-C3alkyl or heterocyclylC0-C3alkyl, R4'' is H or C1-C6alkyl; or R4' and R4'' together with the carbon atom to which they are attached define a C3-C6cycloalkyl; W is H, C1-C6alkyl, C3-C7ycycloalkyl, aryl or heterocyclyl; or a pharmaceutically acceptable salt, hydrate or N-oxide thereof. The compounds of the invention are inhibitors of aspartyl proteases such as renin and are among other things useful for the treatment of conditions associated with activities of the RAS, such as hypertension, heart failure and renal insufficiency.

3, 4-SUBSTITUTED PYRROLIDINE DERIVATIVES FOR THE TREATMENT OF HYPERTENSION

The invention relates to the use of (3,4-di-, 3,3,4-tri, 3,4,4-tri- or 3,3,4,4-tetra-)substituted pyrrolidine compounds for the preparation of a pharmaceutical formulation for the treatment of a disease that depends on activity of renin; the use of a compound of that class in the treatment of a disease that depends on activity of renin; compounds that are part of a subclass of these substituted pyrrolidine compounds for use in the diagnostic and therapeutic treatment of a warm-blooded animal, especially for the treatment of a disease (= disorder) that depends on activity of renin; new compounds that are part of a subclass of these substituted pyrrolidine compounds; pharmaceutical formulations comprising said substituted pyrrolidine compounds, and/or a method of treatment comprising administering said substituted pyrrolidine compounds, a method for the manufacture especially of said new substituted pyrrolidine compounds, as well as novel intermediates, starting materials and/or partial steps for their synthesis. The substituted pyrrolidine compounds are of the formula (I), wherein R1, R2, R3, R4, R5 and T are defined as in the specification.